Liquidia Corporation: A Strong Buy in the Biopharmaceutical Industry (Focused on Cardiopulmonary Therapies)

• Raymond James has reiterated a “Strong Buy” rating for NASDAQ:LQDA, with a recent price target of $47.
• Liquidia Corporation reported Q4 2025 earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.08.
• The company achieved revenue of $92.02 million for the quarter, surpassing expectations by 19.34%.

Liquidia Corporation (NASDAQ: LQDA) is a biopharmaceutical company dedicated to developing and commercializing innovative inhaled therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead product, YUTREPIA (treprostinil inhalation powder), was launched in 2025 and has driven rapid revenue growth.

As of March 5, 2026, Raymond James reiterated its “Strong Buy” rating on LQDA (with a $47 price target in recent updates), following the company’s Q4 2025 earnings release.

Liquidia’s financial performance was impressive. For the fourth quarter ended December 2025, the company reported earnings of $0.15 per share, significantly surpassing the Zacks Consensus Estimate of $0.08. This compares to a loss of approximately $0.46 per share in the year-ago quarter. The company swung to profitability in Q4, with net income of ~$14.6 million and positive adjusted EBITDA.

Revenue reached $92.02 million (primarily from YUTREPIA net product sales of ~$90.1 million), exceeding the Zacks Consensus Estimate by 19.34%. This represents massive growth from $2.92 million in the prior-year quarter, reflecting the successful commercial launch of YUTREPIA in June 2025 (with full-year 2025 sales of ~$148.3 million and over 2,900 patients treated). Over recent quarters, Liquidia has consistently beaten revenue estimates.

Despite the strong results, LQDA stock experienced some pressure post-earnings, trading around $33–$34. It traded between lows in the $31s and highs near $35 recently. Over the past year, the stock has ranged from a low of ~$11.26 to a high of ~$46.67.

Liquidia’s market capitalization is approximately $3 billion, with average daily trading volume in the millions of shares. The robust Q4 performance, ongoing YUTREPIA adoption, cash position (~$190.7 million at year-end 2025), and analyst support (including Raymond James’ Strong Buy) underscore significant growth potential in the pulmonary hypertension space, though the company continues to invest in pipeline expansion (e.g., L606 for sustained-release delivery).